One of the aspects that we didn’t touch on today is that the rights to cardio-protection drug combinations could be licensed separately to the FTO rights. They could also be licensed in different geographical regions separately. Today’s announcement really does open up a huge amount of commercialisation flexibility and potential.
Ann: Breakthrough Zantrene Heart Protection Discovery, page-119
-
- There are more pages in this discussion • 248 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.055(3.82%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.46 | $50.72K | 34.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6138 | $1.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 1400 | 1 |
View Market Depth
| Last trade - 10.10am 12/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |